Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2015 and headquartered in Hong Kong, ORI Capital is a venture capital firm that specializes in early-stage investments within the biotech sector. The firm has established a reputation for its targeted approach to investing in innovative companies that focus on diagnostics, drug delivery, and therapeutics. ORI Capital's investment strategy is particularly concentrated on high-mortality disease areas, including cancer, cardiovascular diseases, and neurodegenerative disorders. With a commitment to addressing critical health challenges, ORI Capital aims to support the development of transformative therapies that can significantly improve patient outcomes.
Since its inception, ORI Capital has raised multiple funds and has built a diverse portfolio of investments in the biotech space. The firm employs a proprietary quantimental strategy that combines AI-assisted big data analytics with fundamental research to identify promising startups. This unique approach allows ORI Capital to stay ahead of industry trends and make informed investment decisions. The firm’s leadership team comprises specialists with extensive expertise in data science and scientific research, enabling them to evaluate potential investments rigorously.
ORI Capital's investment focus is on early-stage biotech companies that are innovating in the fields of diagnostics, drug delivery, and therapeutics. The firm specifically targets sectors that address high-mortality diseases, which include but are not limited to cancer, cardiovascular diseases, and neurodegenerative disorders. By concentrating on these critical areas, ORI Capital aims to back companies that have the potential to make a significant impact on public health.
The firm typically invests at the Seed and Series A stages, providing essential capital to startups that are in the early phases of development. ORI Capital seeks to partner with visionary founders who are dedicated to advancing healthcare solutions and who possess a strong understanding of their respective markets. The firm looks for innovative technologies and business models that can disrupt traditional approaches to treatment and diagnosis, thereby improving patient care and outcomes.
One of ORI Capital's notable portfolio companies is Semma Therapeutics, which is focused on developing groundbreaking therapies for patients who rely on insulin injections. Semma Therapeutics utilizes Induced Pluripotent Stem Cell (iPS) derived pancreatic islets to create potential cures for insulin-dependent diabetes. This innovative approach exemplifies ORI Capital's commitment to investing in companies that are at the forefront of biotech advancements and are working to address significant health challenges.
While Semma Therapeutics stands out as a key investment, ORI Capital maintains a diverse portfolio that spans various sectors within the biotech industry. The firm continues to seek out additional opportunities to invest in companies that align with its mission of improving health outcomes through innovative solutions.
To pitch ORI Capital, please email your proposal to info@ori-capital.com. Ensure your pitch includes a clear description of your business model, technology, and the specific health challenges you aim to address. ORI Capital is open to both warm introductions and cold applications, but a well-structured pitch is essential for consideration.
ORI Capital invests primarily in the Seed and Series A stages of startup development. This focus allows them to support early-stage companies that are poised for growth and innovation in the biotech sector.
Founders interested in pitching to ORI Capital can reach out via email at info@ori-capital.com. It is advisable to provide a clear and concise overview of your business, including your technology, market potential, and how your solution addresses high-mortality diseases.
ORI Capital specializes in the biotech sector, with a particular emphasis on diagnostics, drug delivery, and therapeutics. The firm targets companies that are developing solutions for high-mortality diseases such as cancer and cardiovascular conditions.
The specific check size for investments by ORI Capital is not disclosed in the available information. However, as a venture capital firm, they typically provide funding that aligns with the needs of early-stage biotech companies.
ORI Capital invests globally, seeking innovative biotech companies from various regions that align with their investment thesis focused on high-mortality diseases.
While specific details on portfolio support are not provided, ORI Capital's team includes specialists with diverse expertise, which suggests they may offer valuable insights and guidance to their portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.